Parker Waichman LLP Represents Pennsylvania Man in Lawsuit Alleging Actos Caused his Bladder Cancer

Share Article

Takeda’s diabetes drug Actos (pioglitazone) allegedly caused bladder cancer, according to a lawsuit filed by Parker Waichman LLP on behalf of a Pennsylvania man. The suit is among the thousands consolidated into the Actos multidistrict litigation, in which the law firm’s founding partner, Jerrold S. Parker, serves on the Plaintiffs’ Steering Committee.

News Image
The suit alleges that the Defendants knew about the risk of bladder cancer but failed to disclose this information to consumers in order to protect financial interests.

Parker Waichman LLP, a national law firm dedicated to protecting the victims of defective drugs, has filed a lawsuit on behalf of a Pennsylvania man who allegedly developed bladder cancer after taking the diabetes drug Actos (pioglitazone). The suit was filed on May 23rd in the U.S. District Court for the Western District of Louisiana (Case No. 6:13-cv-1170) as part of the multidistrict litigation entitled In Re: Actos (Pioglitazone) Products Liability Litigation (6:11-md-2299). Takeda Pharmaceuticals, America; Takeda Pharmaceuticals USA, Inc. f/k/a Takeda Pharmaceuticals North America, Inc.; Takeda Pharmaceutical Company Limited; and Eli Lilly and Company have been named as Defendants.

According to the Complaint, the Plaintiff started taking Actos in November 2003 to treat his Type 2 diabetes. By August 2006, he was diagnosed with bladder cancer. The suit alleges that Actos caused the bladder cancer due to its defective nature. Furthermore, the suit alleges that the Defendants knew about the risk of bladder cancer but failed to disclose this information to consumers in order to protect financial interests. The Plaintiff is alleging that Actos caused pain and suffering, emotional distress and economic damages in the form of medical expenses and lost wages. The suit is also seeking damages for loss of consortium on behalf of the Plaintiff’s spouse.

In June 2011, the U.S. Food and Drug Administration (FDA) warned that taking Actos for more than a year could significantly increase the risk of bladder cancer. The safety label on Actos was updated to address this risk*. Additional research supports the link between Actos and bladder cancer. Last May, a study in the British Medical Journal** found that Actos users were twice as likely to develop bladder cancer after two years. That July, the Canadian Medical Association Journal*** found that patients taking the medication were 22 percent more likely to get bladder cancer.
*http://www.fda.gov/Drugs/DrugSafety/ucm266555.htm
**(http://www.bmj.com/content/344/bmj.e3645)
***(http://www.cmaj.ca/content/early/2012/07/03/cmaj.112102)

Parker Waichman LLP continues to offer free legal consultations to victims of Actos injuries, including bladder cancer, heart problems, and eye injuries. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

Contact:
Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636
http://www.yourlawyer.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Gary Falkowitz
Follow us on
Visit website